Last updated on April 2020

Contribution of the Imaging to the Expression of int grines v 3 for the Characterization of Residual Masses of Non-seminoma Tumors at the End of Chemotherapy

Brief description of study

The purpose of this study is to evaluate the contribution of the imaging to the expression of intgrines v3 for the characterization of the residual masses of non-seminoma tumors at the end of chemotherapy.

The investigators hope that the results of this first stage of the clinical trial come to consolidate the preclinical results obtained by the investigators team to characterizing the interest and the strong contribution of the use of a tracer resting on the expression of v3 integrine for the diagnosis of simple necrosed mass at the end of the treatment of a non-seminoma tumor, so allowing to defer a surgery to about 40 % of the patients.

Clinical Study Identifier: NCT02317393

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.